For more than two decades, endocrine drug development in estrogen receptor-positive breast cancer was defined largely by aromatase inhibitors, tamoxifen and fulvestrant. That landscape is now changing quickly.
Oral selective estrogen receptor degraders, or oral SERDs, have moved from an experimental strategy for endocrine-resistant metastatic disease into a broader therapeutic platform encompassing ESR1-directed treatment after progression, combination therapy, ctDNA-guided intervention before radiographic progression and, increasingly, curative-intent early breast cancer.
That evolution makes oral SERDs particularly relevant to the discussions around OncoDaily Mammo 2026. For clinicians, the questions concern patient selection and sequencing. For translational researchers, they concern ESR1 evolution and molecular monitoring. For the pharmaceutical community, the competition is increasingly about something larger than which molecule degrades ER most effectively: where in the disease course the drug is positioned, which biomarker activates its use, which partner therapy accompanies it and whether it can improve outcomes before conventional progression occurs.
Register for Mammo 2026: Global Breast Cancer Virtual Congress
A July 2026 review in JCO Oncology Practice described this rapidly changing space as the emerging integration of new ER-directed and precision therapies, emphasizing that treatment selection is becoming increasingly biomarker driven while optimal sequencing remains unresolved (Lloyd et al., 2026).
Why Has Estrogen Receptor Degradation Become More Important?
The estrogen receptor remains a central therapeutic dependency in HR-positive/HER2-negative breast cancer, even after tumors become resistant to conventional endocrine therapy.
One of the most important mechanisms of acquired endocrine resistance is mutation of ESR1, the gene encoding ERα. These mutations can produce constitutive receptor activity, allowing estrogen-responsive transcription to continue despite estrogen deprivation.
This biology is particularly relevant after exposure to aromatase inhibitors and CDK4/6 inhibitors and provides a strong rationale for therapies that directly antagonize and degrade the receptor rather than only reducing estrogen availability (Lloyd et al., 2026).
New mechanistic research published in Nature in 2026 adds another dimension to this rationale.
Watt and colleagues demonstrated that CDK4/6 inhibition activates hypophosphorylated Rb as expected, suppressing E2F-mediated cell-cycle transcription. But activated Rb also moved into ER-rich chromatin networks and increased expression of estrogen-responsive genes, including CCND1. In endocrine-sensitive models, direct ER inhibition could suppress this compensatory transcriptional response. In ESR1-mutant models, however, the ER program persisted during estrogen deprivation, whereas pharmacologic ER degradation restored deeper cell-cycle suppression (Watt et al., 2026).
The finding does not establish a new treatment standard by itself, but it reinforces an increasingly important concept: effective CDK4/6 inhibition and effective ER suppression are biologically interconnected rather than independent therapeutic strategies.
Why Was Fulvestrant Not the Final Answer?
Fulvestrant established the clinical principle that directly degrading ER could treat endocrine-resistant disease. But its intramuscular administration and pharmacologic characteristics created a rationale for developing orally bioavailable agents capable of achieving sustained systemic ER antagonism and degradation.
The oral SERD field subsequently became crowded, and importantly, clinical development has shown that SERDs cannot be treated as an automatically successful drug class.
Different agents have produced different results according to population, biomarker status, treatment line and combination partner. The development history itself has therefore become informative: a molecule that appears active in ESR1-mutated disease after CDK4/6 exposure does not necessarily outperform standard endocrine therapy in an unselected population.
That distinction is now shaping both clinical development and pharmaceutical strategy (Lloyd et al., 2026).
Elacestrant Made ESR1 a Treatment-Selection Biomarker
The phase III EMERALD trial represented the first major proof that an oral SERD could improve outcomes in previously treated advanced breast cancer.
The study randomized patients with ER-positive/HER2-negative advanced or metastatic breast cancer who had previously received endocrine therapy and a CDK4/6 inhibitor to oral elacestrant or investigator-selected endocrine therapy.
In the overall population, median progression-free survival was 2.8 months with elacestrant versus 1.9 months with standard endocrine therapy, corresponding to an HR of 0.70.
The difference became more pronounced in patients whose tumors carried ESR1 mutations: median PFS was 3.8 versus 1.9 months, with an HR of 0.55 (Bidard et al., 2022).
Subsequent analyses suggested that previous duration of endocrine sensitivity mattered. Among ESR1-mutated patients who had received endocrine therapy plus a CDK4/6 inhibitor for at least 12 months, median PFS with elacestrant reached 8.6 months versus 1.9 months with standard therapy (Bardia et al., 2024).
The EMERALD results led to the 2023 US approval of elacestrant for selected patients with ER-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression on endocrine therapy.
From a drug-development perspective, the larger lesson was as important as the approval itself: ESR1 mutation was not simply a resistance marker. It became a biomarker capable of defining a population in which a next-generation ER-directed therapy had greater clinical relevance.
Imlunestrant Expanded the Question From Monotherapy to Platform Combination
The phase III EMBER-3 trial moved the field further.
Among 874 patients with ER-positive/HER2-negative advanced breast cancer whose disease had recurred or progressed during or after aromatase inhibitor therapy, imlunestrant was evaluated against standard endocrine therapy, while a separate randomized comparison examined imlunestrant plus abemaciclib versus imlunestrant alone.
In the ESR1-mutated population, imlunestrant monotherapy improved median PFS to 5.5 months versus 3.8 months with standard endocrine therapy, with an HR of 0.62.
However, in the overall population, imlunestrant monotherapy did not significantly improve PFS: 5.6 versus 5.5 months (Jhaveri et al., 2025).
That difference again reinforced ESR1 as an important determinant of monotherapy benefit.
The combination result told a different story. Imlunestrant plus abemaciclib significantly improved PFS compared with imlunestrant alone irrespective of ESR1 status. At the primary analysis, median PFS was 9.4 versus 5.5 months, and updated results subsequently reported 10.9 versus 5.5 months, with an HR of 0.59 (Jhaveri et al., 2025; Jhaveri et al., 2026).
The FDA approved imlunestrant in September 2025 for adults with ER-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression following at least one endocrine therapy.
For the pharmaceutical community, EMBER-3 illustrates a major strategic distinction: the value of an oral SERD can depend on whether it is being developed as a biomarker-selected monotherapy or as the endocrine backbone of a combination regimen.
Those are different development propositions.
SERENA-6 Changed the Timing of the SERD Question
Perhaps the most disruptive oral SERD concept has come from the phase III SERENA-6 trial.
Traditionally, a patient receiving an aromatase inhibitor plus a CDK4/6 inhibitor remains on treatment until clinical or radiographic progression. SERENA-6 challenged that model by asking whether endocrine therapy should be changed when molecular resistance appears before the cancer visibly progresses.
Patients receiving first-line aromatase inhibitor plus CDK4/6 inhibition underwent serial ctDNA testing. When an ESR1 mutation emerged in circulating tumor DNA without radiographic progression, patients were randomized either to switch from the aromatase inhibitor to camizestrant while continuing the same CDK4/6 inhibitor, or to continue the existing aromatase inhibitor-CDK4/6 regimen.
Median PFS was:
- 16.0 months with camizestrant plus CDK4/6 inhibition
versus
- 9.2 months with continued aromatase inhibitor plus CDK4/6 inhibition.
The HR for progression or death was 0.44, corresponding to a 56% relative risk reduction (Bidard et al., 2025).
This is more than another positive SERD trial.
SERENA-6 effectively changed the therapeutic question from:
- Which endocrine drug should we use after progression?
to:
- Should molecular resistance itself become the trigger to change treatment?
ctDNA Is Becoming Part of the Drug-Development Strategy
SERENA-6 is especially relevant to the pharma and diagnostics communities because the therapeutic strategy depends on serial molecular surveillance.
The drug and the biomarker are functionally linked.
Without repeated ctDNA testing, there is no defined moment at which the SERENA-6 intervention takes place. The treatment strategy therefore requires not only an active oral SERD but also a reproducible ESR1 assay, a surveillance schedule, clinical pathways for interpreting molecular progression and healthcare infrastructure capable of acting before imaging progression.
This represents a broader evolution in precision oncology: pharmaceutical development can increasingly depend on when a biomarker is measured, not simply whether a biomarker is present.
That distinction is likely to become one of the most important discussions around oral SERDs at Mammo 2026.
Camizestrant Also Shows Why Regulatory Strategy Matters
SERENA-6 has also produced an unusually instructive regulatory story.
In July 2026, camizestrant received EU marketing authorization in combination with a CDK4/6 inhibitor for adults with ER-positive/HER2-negative locally advanced or metastatic breast cancer with an ESR1 mutation detected without disease progression during first-line endocrine therapy plus CDK4/6 inhibition.
The US regulatory discussion has been more cautious.
In April 2026, the FDA’s Oncologic Drugs Advisory Committee voted 6 to 3 against the proposition that SERENA-6 had demonstrated clinically meaningful benefit sufficient for the proposed pre-progression indication. FDA reviewers highlighted uncertainty around long-term benefit, including immature overall survival data, while some committee members supporting the application considered the delay in progression clinically meaningful.
The contrast is important for drug developers.
The challenge is no longer simply demonstrating that a targeted intervention improves PFS. Pre-progression treatment switching raises different questions about endpoints, overall treatment strategy, duration of therapy, potential overtreatment and the level of evidence required to justify acting on a biomarker before conventional progression.
SERENA-6 may therefore become as influential for precision-oncology trial design as it is for oral SERD development.
Giredestrant Is Moving the Class Into Early Breast Cancer
The next major frontier is even larger: curative-intent disease.
In the phase III lidERA Breast Cancer trial, 4,170 patients with ER-positive/HER2-negative early breast cancer were randomized to adjuvant giredestrant or standard endocrine therapy.
At the primary analysis, giredestrant reduced the risk of invasive disease recurrence or death by approximately 30%:
HR 0.70; 95% CI, 0.57–0.87
Three-year invasive disease-free survival was:
- 92.4% with giredestrant
versus
- 89.6% with standard endocrine therapy.
Overall survival remained immature (Bardia et al., 2026).
The absolute difference at three years is smaller than the relative hazard reduction might initially suggest, and longer follow-up is particularly important in ER-positive early breast cancer because recurrence risk extends over many years.
Still, lidERA represents a major change in the oral SERD development story: the class is no longer confined to rescue therapy after acquired endocrine resistance.
Giredestrant is now under FDA priority review for this early-stage setting based on the lidERA results.
Early Disease Changes the Commercial and Clinical Questions
Moving an oral SERD into adjuvant breast cancer is fundamentally different from using it after metastatic progression.
Treatment can continue for years. The treated population is substantially larger. Most patients are disease free at the time therapy begins. Consequently, tolerability, adherence, drug interactions, quality of life and long-term safety become even more important.
The clinical comparator also changes.
An oral SERD in early breast cancer is competing not only with another endocrine molecule but with decades of experience using aromatase inhibitors and tamoxifen, therapies with established efficacy, low acquisition costs and very long follow-up.
At the same time, higher-risk patients increasingly receive adjuvant CDK4/6 inhibitors. The future development question therefore becomes whether an oral SERD replaces standard endocrine therapy, becomes the preferred partner for CDK4/6 inhibition, follows a CDK4/6 inhibitor, or is reserved for molecularly defined high-risk populations.
For pharmaceutical portfolios, this means that success in early disease will depend on much more than demonstrating ER degradation.
Giredestrant Also Shows Why Oral SERDs Are Not Interchangeable
The development history of giredestrant is particularly informative.
In the randomized phase II acelERA Breast Cancer trial in previously treated ER-positive/HER2-negative advanced disease, giredestrant did not significantly improve investigator-assessed PFS compared with physician’s choice endocrine therapy in the overall population:
- HR 0.81; 95% CI, 0.60–1.10; P=0.1757.
A stronger numerical signal was observed in patients with ESR1-mutated tumors, but the overall primary endpoint was not met (Martín et al., 2024).
Yet the same molecule subsequently generated positive phase III signals in other contexts, including adjuvant lidERA.
That is an important lesson for the entire field.
A negative result in one treatment line does not necessarily invalidate an ER degrader, just as activity in one ESR1-selected metastatic population does not guarantee success in an unselected one.
Indication design is becoming as important as molecule design.
The Next Competition Is About More Than ESR1
ESR1 has become the clearest biomarker for oral SERD sensitivity after endocrine exposure, but it will not be the only determinant of treatment choice.
HR-positive/HER2-negative metastatic breast cancer increasingly contains overlapping actionable alterations involving pathways such as PI3K/AKT/mTOR, while resistance can remain ER dependent, become partly ER independent or evolve through several mechanisms simultaneously.
The 2026 JCO Oncology Practice review emphasizes that the optimal sequence becomes particularly difficult when tumors harbor more than one actionable alteration, for example, concurrent ESR1 and PIK3CA changes, because multiple biomarker-directed therapeutic options can become available (Lloyd et al., 2026).
For developers, this creates a combination problem.
The next-generation endocrine backbone must be compatible not only with CDK4/6 inhibitors but potentially with PI3K-, AKT- or mTOR-directed therapies and other precision combinations.
As a result, safety profile, pharmacokinetics and combination flexibility can become competitive differentiators alongside single-agent efficacy.
The ER-Degrader Market Is Already Expanding Beyond SERDs
Oral SERDs are also no longer competing only against one another.
A separate approach uses PROTAC technology to recruit the cellular protein-degradation machinery directly to ER.
In the phase III VERITAC-2 trial, vepdegestrant, a PROTAC ER degrader, significantly prolonged PFS compared with fulvestrant in patients with ESR1-mutated ER-positive/HER2-negative advanced breast cancer, although superiority was not demonstrated in the full randomized population.
The FDA approved vepdegestrant in May 2026 for ESR1-mutated ER-positive/HER2-negative advanced or metastatic breast cancer after progression following endocrine therapy.
Vepdegestrant is not an oral SERD, and that distinction should remain clear. But its emergence demonstrates that the commercial and scientific contest is broadening from “which SERD?” toward which method of eliminating ER activity provides the most useful clinical profile?
What Will Differentiate the Next Oral SERD?
The first generation of oral SERD competition focused heavily on pharmacologic potency and the ability to degrade mutant ER.
The next stage will require differentiation across several clinical dimensions.
A successful molecule may need to demonstrate that it can work after CDK4/6 inhibition, retain activity against ESR1-mutated tumors, combine cleanly with targeted agents, function in earlier disease, support long treatment duration and fit naturally into biomarker-driven treatment algorithms.
The most strategically valuable asset may therefore not simply be the drug with the strongest laboratory degradation percentage.
It may be the drug with the strongest clinical development ecosystem around it.
That includes companion diagnostics, ctDNA integration, appropriate combination partners, evidence in both metastatic and early-stage disease, patient-reported outcomes and a trial program capable of defining precisely when the drug should replace another endocrine therapy.
Mammo 2026: The Oral SERD Conversation Is Now Bigger Than a Drug Class
This is why oral SERDs are particularly relevant to OncoDaily Mammo 2026.
For the oncology community, one discussion is about sequencing: elacestrant, imlunestrant, camizestrant, giredestrant and other ER-directed strategies cannot simply be placed in a single interchangeable category.
For the diagnostics community, SERENA-6 raises the question of whether serial ESR1 monitoring should become part of active treatment management rather than a test ordered only after progression.
For translational researchers, the 2026 Nature study adds another question: could the transcriptional consequences of CDK4/6-mediated Rb activation help identify settings in which direct ER degradation is particularly important?
And for pharmaceutical developers, the stakes are expanding rapidly from a relatively defined post-CDK4/6 metastatic population into first-line molecular interception and potentially the much larger adjuvant setting.
The oral SERD race is therefore becoming a test of drug development strategy, biomarker strategy and treatment architecture simultaneously.
The Bottom Line
Oral SERDs have already passed several important milestones.
Elacestrant demonstrated that an oral SERD could improve outcomes after endocrine therapy and made ESR1 mutation a clinically actionable treatment-selection biomarker.
Imlunestrant confirmed activity in ESR1-mutated disease while showing that an oral SERD can also function as the endocrine backbone of a CDK4/6 combination.
Camizestrant pushed the strategy one step earlier by using serial ctDNA to identify ESR1-mediated resistance and changing endocrine therapy before radiographic progression, extending median PFS from 9.2 to 16.0 months in SERENA-6.
Giredestrant has now moved the oral SERD discussion into curative-intent treatment, with lidERA reporting a 30% relative reduction in invasive recurrence or death compared with standard adjuvant endocrine therapy.
At the same time, mixed results across trials show that there is no universal “oral SERD effect.” Benefit depends on biology, ESR1 status, treatment line, partner therapy and timing.
That may ultimately be the most important message for Mammo 2026.
The next phase of endocrine drug development is not simply about building a better fulvestrant.
It is about deciding when to degrade ER, how early to recognize endocrine resistance, what therapy to combine with ER degradation and whether molecular evolution can be intercepted before it becomes clinical progression.
For both the breast oncology and pharmaceutical communities, oral SERDs are increasingly becoming less of a drug class and more of a new precision-endocrine treatment platform.
References
- Watt AC, Ahn A, Blyth C, et al. Rb-driven transcription limits its tumour-suppressive effects in breast cancer. Nature. 2026. doi:10.1038/s41586-026-10886-w.
- Lloyd MR, Shatsky RA, Love N, Wander SA. SERD Wars: Clinical Integration of Emerging Endocrine-Directed and Precision Therapies in Breast Cancer. JCO Oncology Practice. 2026. doi:10.1200/OP-26-00199.
- Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant in estrogen receptor-positive/HER2-negative advanced or metastatic breast cancer: results from the randomized phase III EMERALD trial. Journal of Clinical Oncology. 2022.
- Bardia A, et al. Elacestrant in ER-positive/HER2-negative metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from EMERALD. Clinical Cancer Research. 2024.
- Jhaveri KL, et al. Imlunestrant with or without abemaciclib in advanced breast cancer. New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2410858.
- Jhaveri KL, et al. Updated efficacy results from the phase III EMBER-3 trial. Annals of Oncology. 2026.
- Bidard FC, et al. First-line camizestrant for emerging ESR1-mutated advanced breast cancer. New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2502929.
- Martín M, et al. Giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer: results from the randomized phase II acelERA Breast Cancer study. Journal of Clinical Oncology. 2024.